A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors
- Sponsor:
- BioNTech Pharmaceuticals
- Sponsor Study ID:
- BNT317-01/PM1086-A001
- CTO #:
- 104114
- NCT Number:
- NCT06750185
- Phase:
- I
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Bladder; Breast; Cervix Uteri; Colon; Esophagus; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Ovary; Pancreas; Prostate; Rectum; Small Intestine
- Study Objectives:
- To determine the safety profile, and tolerability of BNT317 in patients with advanced solid tumors. To determine the MTD or the RP2D of BNT317 in patients with advanced solid tumors.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Kaczmar, John, at kaczmar@musc.edu , or please call +1 843-792-6691.
- Study Coordinator, Boggan, Holly, at bogganhl@musc.edu , or please call +1 843-792-8068.
Trial opened at the following institutions:
Medical University of South Carolina